Chemotherapy-Induced Peripheral Neuropathy Market to Witness Significant Growth at a CAGR of 14.2% During the Forecast Period (2026-2036) as Novel Therapies Enter Late-Stage Development | DelveInsight
The growing market of chemotherapy-induced peripheral neuropathy is driven by high prevalence, significant unmet need, and the increasing use of neurotoxic chemotherapies. Growing emphasis on survivorship and quality of life, along with the emergence of mechanism-based, disease-modifying...
The growing market of chemotherapy-induced peripheral neuropathy is driven by high prevalence, significant unmet need, and the increasing use of neurotoxic chemotherapies. Growing emphasis on survivorship and quality of life, along with the emergence of mechanism-based, disease-modifying...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.